HONG KONG, Aug. 6, 2025 /PRNewswire/ — Bayes Labs team announces that Bayes Market, the prediction platform launched in July pioneering the next wave of decentralized information infrastructure, has secured $2 million strategic investment from a group of investors. The investors include institutional participation from Singapore’s GreenVision Fund, Jkapital Ltd., and Bearcat, alongside a prominent U.S. public company chairman. This diverse investor group shares a unified conviction: prediction markets represent a transformational shift in how society generates, exchanges, and values information.

These funds will accelerate Bayes Market’s product development, regional expansion, and user growth—particularly across Asia, where social and cultural dynamics align naturally with prediction markets. According to the CEO of GreenVision, “Prediction markets are not just a trend—they are the future of how societies find a shared-reality in complex world. Bayes team has the right vision to scale this movement.”

Mass Adoption Underway

The year 2025 marks a turning point for the prediction market industry. Polymarket’s integration with X and Kalshi’s $2B valuation signal that the industry is moving towards the mainstream. As trust in centralized narratives erode, prediction markets offer a credible, participatory alternative—surfacing diverse viewpoints and aligning incentives for individual expression.

Prediction markets were never by nature solely for crypto-native users. Human beings are inherently driven to predict. Whether guessing the outcome of a reality show or speculating on political developments, people engage in informal forecasting daily. Prediction markets formalize this instinct, offering structure, visibility, and rewards. They are not tools for speculators alone—they are an evolution of how people interact with real-world uncertainty.

Bayes Market distinguishes itself by focusing on intuitive design, culturally relevant markets across Asia and a strong emphasis on user empowerment. These features enable a familiar, social, and gamified experience—they are social signals embedded in daily life. 

A New Intelligence Infrastructure for a Decentralized Future

As demand grows for open, transparent, and decentralized systems, prediction markets are poised to become a core infrastructure of the information economy. Bayes Market is not just building a product—it is building a public good: a participatory framework for decentralized intelligence. 

In an age defined by uncertainty, Bayes Market innovates prediction markets holding the belief that they are not an anomaly of crypto—they are the natural evolution of how society as a whole engages with the future.

PANAMA CITY, Aug. 6, 2025 /PRNewswire/ — BingX, a leading cryptocurrency exchange and Web3 AI company, successfully wrapped up its participation at GM Vietnam 2025, one of Southeast Asia’s largest blockchain gatherings. Vivien Lin, Chief Product Officer at BingX, delivered a keynote speech outlining BingX’s vision for the future of Web3 and AI, and detailed how BingX’s AI Evolution strategy is delivering more innovative and accessible experiences for users.

Vivien emphasized that the next chapter of digital assets will not be driven by speculation or hype, but by intelligence. By breaking down common barriers such as fragmented tools, information overload, and lack of confidence, BingX AI learns and grows together with its users — creating what BingX defines as financial dignity —  empowering them to make confident, informed decisions without being hindered by complexity.

Backed by a $300 million investment over three years, BingX’s AI Evolution strategy encompasses the establishment of the BingX AI Institute and the fostering of AI-driven Web3 projects through its arms like BingX Labs, reaffirming BingX’s long-term vision: to make digital assets not only accessible, but intelligent — creating a trading experience that is real-time, adaptive, and built around users’ needs.

Speaking of BingX’s vision for the market and the industry, Vivien commented: “Vietnam is emerging as one of Asia’s most dynamic blockchain communities, and events like GM Vietnam show how quickly the industry is evolving. This year, we shared how AI can bring greater dignity and agency to digital asset trading by making it more intelligent, accessible, and user-driven. BingX is committed to applying this vision not only globally, but here in Vietnam, supporting the community with innovative AI-powered tools and long-term expertise.”

Looking ahead, BingX will continue advancing its AI-powered trading solutions while deepening its roots in Vietnam and the broader Southeast Asia region. With a focus on user-centric innovation, strategic partnerships, and localized support, BingX remains committed to shaping a more intelligent, inclusive, and empowered future for digital asset traders worldwide.

About BingX 

Founded in 2018, BingX is a leading crypto exchange and Web3 AI company, serving a global community of over 20 million users. With a comprehensive suite of AI-powered products and services, including derivatives, spot trading, and copy trading, BingX caters to the evolving needs of users across all experience levels, from beginners to professionals. Committed to building a trustworthy and intelligent trading platform, BingX empowers users with innovative tools designed to enhance performance and confidence. In 2024, BingX proudly became the official crypto exchange partner of Chelsea Football Club, marking an exciting debut in the world of sports sponsorship.

For more information please visit: https://bingx.com/

TAIPEI, Aug. 6, 2025 /PRNewswire/ — Taiwanese jewelry artist Karjengon Wu has forged a distinctive design language that seamlessly integrates art, culture, aesthetics, and brand management. With this multifaceted creative power, he has risen to prominence in the international jewelry scene. His works are not merely accessories, but wearable art pieces—cultural vessels that transcend borders—earning acclaim and admiration across the global fashion world.

Wu is the founder of T.THREE Jewelry, a brand he co-created with design partner Yi-Wen Lin. Together, they have produced numerous captivating collections favored by global dignitaries and social elites. Notable collectors of his work include Palau‘s Goodwill Ambassador Ms. Chia-Ju Tsai, Mrs. Paine, wife of the Haitian Ambassador, and Abigail Beatrice, First Secretary of the Eswatini Embassy—each representing the international appeal of Wu’s creations.

Mayor Bertrick of Moret-sur-Loing, France, personally collected one of Wu’s signature pieces, praising its exquisite craftsmanship and the profound beauty of Eastern design. He described the work as a “cultural bridge” between France and Taiwan. Madame Dominique, Chair of the French Association of Painters and Calligraphers, also collected Wu’s award-winning piece “Elegant Orchid Spirit“, which received honors at the International Orchid Handicraft Competition—further affirming Wu’s artistic impact on the global stage.

Wu’s creations have also been embraced by the fine art community. Ho Wen-Chi, a nationally honored painter recognized by Taiwan’s Ministry of Culture, is a devoted wearer of Wu’s pieces, commending the harmonious balance of colors and gemstones. The late master of ink painting, Lee Chi-Mao, also collected Wu’s jewelry and inscribed a personalized calligraphy piece in tribute:
“Mr. Karjengon—Master of Exquisite Eastern Craftsmanship,” adding a layer of artistic resonance to Wu’s design legacy.

Karjengon Wu’s design language is highly distinctive. Whether working in minimalism, Baroque, naturalism, futurism, or ethnic styles, each collection presents a uniquely interpreted aesthetic. He boldly incorporates unconventional materials such as wood, shells, resin, and recycled elements, utilizing wax carving, micro-sculpting, and mixed media to break free from traditional jewelry frameworks.

His works have been showcased at numerous international exhibitions in cities such as Paris, Beijing, Chongqing, and Tokyo, highlighting Taiwan’s creative spirit and rich design diversity on a global scale—enhancing the island’s visibility and influence in the realm of cultural diplomacy.

Selected International Exhibitions & Events:

• 2012 – Greater China Jewelry Designers Joint Exhibition, Beijing, China (Taiwan Representative)
• 2012 – China International Jewelry Masters Forum, Beijing Caibai
• 2013 – Shenzhen International Cultural Industries Fair, Jewelry Pavilion
• 2014 – East-West Art Exchange Exhibition at the Louvre, Paris
• 2014 – Awarded artist in the Taiwan Tour of the Louvre’s East-West Art Exhibition (Kaohsiung)
• 2015 – International Art Expo at Pierre Cardin Art Center, Paris – attended by Laotian princess and 8th arrondissement mayor Jeanne d’Hauteserre
• 2017 – Jewelry showcase and forum hosted by China’s Taiwan Affairs Office in Chengdu
• 2019 – Karjengon Wu & Yi-Wen Lin Jewelry Duo Exhibition and Runway Show at Far Eastern Museum THE ONE
• 2022 – Cross-disciplinary showcase combining traditional cheongsam and jewelry at Lin Palace, Kaohsiung
• 2023 – T.THREE Jewelry Show at Kaohsiung Marriott Hotel – featuring Miss Asia Taiwan 3rd runner-up Yu Hsiao-Han wearing Wu’s Louvre gold-winning piece
• 2024 – Jewelry runway show at the Neo-Classical Ladies Club President Handover Ceremony at Lin Palace
• 2025 – Karjengon Wu & Yi-Wen Lin’s stunning runway showcase at Lin Palace again highlighted in a prestigious handover ceremony

A special highlight: Former French Prime Minister Jean-Pierre Raffarin personally visited Wu’s exhibition at the Louvre in 2014 and gave high praise to his jewelry artworks.

Staying true to his mission—“Let Taiwanese design shine confidently on the global stage“—Karjengon Wu continues to root his work in Eastern aesthetics while merging them with contemporary creative expressions. His culturally enriched jewelry art continues to captivate collectors and audiences around the world.

• Brand Information

T.THREE Jewelry
Facebook: https://www.facebook.com/profile.php?id=100063912950648

Original link: https://www.t3-news.com/news_detail.php?NewsID=12708&NewsTitle=%E7%8F%A0%E5%AF%B6%E8%A8%AD%E8%A8%88%E5%B8%AB%E5%90%B3%E4%BD%B3%E6%A5%A8Karjengon%E5%89%B5%E6%84%8F%E8%BB%9F%E5%AF%A6%E5%8A%9B%E5%90%B8%E5%BC%95%E5%9C%8B%E9%9A%9B%E7%9B%AE%E5%85%89

• Birelentinib (DZD8586) received Fast Track Designation from the U.S. FDA for relapsed/refractory CLL/SLL
• Supporting data from a pooled analysis of phase I/II studies of birelentinib showed an objective response rate of 84.2% in heavily pretreated CLL/SLL patients

SHANGHAI, Aug. 6, 2025 /PRNewswire/ — Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its Birelentinib (DZD8586) for the treatment of adult patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

Patients with CLL/SLL treated with a BTK inhibitor or a BCL-2 inhibitor often relapse or progress due to two major resistance mechanisms: BTK C481X mutations and BTK-independent activation of BCR signaling pathway. No targeted therapy currently addresses both mechanisms, posing an urgent clinical challenge. Although BTK degraders have shown encouraging anti-tumor activity in early CLL/SLL clinical studies, mutation-mediated resistance has already been reported, and degrader-associated toxicities may limit their long-term clinical application.

Birelentinib is a first-in-class, non-covalent, LYN/BTK dual inhibitor with full blood-brain barrier (BBB) penetration. It has high selectivity against other TEC family kinases (TEC, ITK, TXK and BMX). By targeting both BTK and LYN, it blocks both BTK-dependent and -independent BCR-signaling pathways, effectively inhibiting tumor growth of B-cell non-Hodgkin lymphomas (B-NHLs).

The Fast Track Designation is supported by data from a pooled analysis of two phase I/II studies of birelentinib in CLL/SLL patients previously treated with covalent/non-covalent BTK inhibitors and BTK degraders. The results were presented at 2025 European Hematology Association (EHA) Annual Congress and featured in oral presentations at both the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the 18th International Conference on Malignant Lymphoma (ICML).

Birelentinib demonstrated significant anti-tumor efficacy in heavily pretreated CLL/SLL patients with an objective response rate (ORR) of 84.2%, with a good safety profile. Tumor responses were observed irrespective of prior treatment with covalent/non-covalent BTK inhibitors, BTK degraders, or BCL-2 inhibitors, including in patients harboring classic BTK resistance mutations (C481X) as well as other BTK mutations, such as kinase-dead mutations. Responses were durable, with an estimated 9-month duration of response (DOR) rate of 83.3%.

“The granting of Fast Track Designation underscores the U.S. FDA’s recognition of birelentinib’s potential to address an unmet medical need in patients with CLL/SLL,” said Dr. Xiaolin Zhang, CEO of Dizal. “We look forward to working closely with the FDA to accelerate the global clinical development of birelentinib and bring this treatment option to patients as quickly as possible.”

Fast Track Designation is an FDA program designed to facilitate the development and expedite the review of drugs for serious conditions that address unmet medical needs. The designation enables for frequent FDA interactions and may allow for rolling revie, priority review, or accelerated approval if criteria are met.

About Birelentinib (DZD8586)

Birelentinib is a first-in-class, non-covalent, LYN/BTK dual inhibitor with full blood-brain barrier (BBB) penetration, designed as a potential treatment option for B-cell non-Hodgkin lymphoma (B-NHL). 

While Bruton’s Tyrosine Kinase (BTK) inhibitors have been approved for the treatment of B-NHL, resistance can arise through two major mechanisms: the BTK C481X mutation and BTK-independent BCR signaling pathway activation. Currently, there is no targeted therapy available to address both resistance mechanisms, posing an urgent clinical challenge. Although BTK degraders have shown encouraging efficacy in early clinical studies, mutation-related resistance has been reported, and degrader-related toxicities may affect long-term clinical application. 

Birelentinib has high selectivity against other TEC family kinases (TEC, ITK, TXK and BMX). By targeting BTK and LYN, it blocks both BTK-dependent and -independent BCR-signaling pathways, effectively inhibiting tumor growth of B-NHLs in cell lines and in animal models. In clinical studies, birelentinib exhibits favorable PK properties, good central nervous system (CNS) permeability, complete blockade of BCR signaling, and encouraging anti-tumor efficacy with good safety and tolerability in patients with B-NHL.

In August 2025, birelentinib was granted Fast Track Designation by the U.S. FDA for the treatment of adult patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

About Dizal

Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs worldwide. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio with multiple assets in global pivotal studies and two leading assets: ZEGFROVY, approved in both the U.S. and China, and golidocitinib, approved in China. To learn more about Dizal, please visit www.dizalpharma.com, or follow us on Linkedin or X.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, and “intend” and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal’s competitive environment, and political, economic, legal, and social conditions.

Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect.

Contacts

Investor Relations: ir@dizalpharma.com
Business Development: bd@dizalpharma.com
Media Contact: pr@dizalpharma.com

NEW YORK, Aug. 6, 2025 /PRNewswire/ — Stavtar Solutions, a leading provider of business spend management and expense allocation SaaS for complex businesses such as alternative asset managers, today announced a Series A investment of $55 million from Elephant. The minority investment will fuel the next phase of expansion for the platform that has revolutionized how complex businesses are managing their business spend, expense allocations, vendors, contracts, budgets, payments, and more. It will drive continued product innovation, expansion of integrated payment capabilities within its flagship product StavPay, as well as hiring to meet rapidly increasing demand.

Co-founded by Steven Petersen and Avtar Batth, a former CFO and CTO respectively, Stavtar was created to solve a problem they lived firsthand: the overwhelming reliance on manual processes and spreadsheets to manage business spend and expense allocations within alternative asset management. With years of navigating operational bottlenecks and fragmented systems, they set out to build a modern, customizable, data-driven platform designed specifically for the needs of finance and operations teams at hedge funds, private equity, family offices, and other complex businesses. Stavtar has grown over 1300% in the past three years and is now the platform of choice for more than 100 alternative asset managers overseeing $2.4 Trillion in AUM. The StavPay platform powers automated workflows for vendor, contract and invoice management, expense allocations, third party payments, budgets, tax filings, custom reporting, and more. It turns their clients’ entire process into approve or reject, while giving them insights into their business like never before, in real time.

“We built Stavtar to fix what we could not ignore – outdated, manual, disconnected financial workflows holding back high-performing teams,” said Steven Petersen, Co-Founder of Stavtar. “Our partnership with Elephant empowers us to focus on what matters most – delivering innovative, enterprise-grade solutions to our clients. We are excited to grow faster, go further, and continue pushing the boundaries of what is possible in software for complex businesses.”

“We engineered Stavtar to address the real pain points faced by complex businesses,” said Avtar Batth, Co-Founder of Stavtar. “This investment enables us to accelerate the development of a scalable, intelligent system designed specifically for the financial and operational realities of alternative asset managers and other sophisticated enterprises.”

This milestone empowers Stavtar to:

• Drive innovation across its portfolio of solutions.
• Grow the engineering, implementation, customer success, and sales teams. 
• Advance its integrated payments platform, including virtual card and vendor payment capabilities.
• Deepen AI and mobile capabilities to put business spend control and insights directly in the hands of CEOs, CFOs, and finance teams. 
• Expand footprint into verticals adjacent to alternative asset management and other similarly complex businesses.

Peter Fallon, Partner at Elephant, will join Stavtar’s board of directors. “Steve and Avtar have built a category-defining platform that solves the complex, high-value challenges confronting some of the most discerning firms in finance,” said Fallon. “We are thrilled to support Stavtar’s vision and help scale its impact through continued market growth.”

With offices in New York, Dallas, London, Mumbai, and Bengaluru, Stavtar is scaling with focus, giving finance teams the tools they need to eliminate manual work, reduce operational risk, increase productivity, and move faster.

About Stavtar

Stavtar is the premier provider of business spend management and expense allocation SaaS solutions built for the Office of the CFO in complex businesses like alternative asset management. Headquartered in New York, with a global footprint spanning Dallas, London, Mumbai, and Bengaluru, Stavtar was founded by seasoned professionals from the alternative asset management industry.

Our flagship business spend management and expense allocation platform, StavPay, empowers over 100 leading alternative asset managers, collectively overseeing more than $2.4 trillion in AUM. 

To learn more, visit www.stavtar.com. 

About Elephant

Elephant is a venture capital firm focused on the enterprise software, consumer internet, and mobile markets.

HONG KONG, Aug. 6, 2025 /PRNewswire/ — On August 6th, Newborn Town (9911.HK) released a positive profit alert for the first half of 2025. The Group achieved rapid revenue expansion alongside a substantial increase in profit, driven by the dual-engine growth of its social networking and innovative businesses.

For the six months ended June 30th, 2025, the Group’s total revenue is estimated to reach RMB 3,135 million and RMB 3,215 million, representing a year-on-year increase of approximately 38% to 41.5%. Profit attributable to equity shareholders of the company is expected to range from RMB 470 million to RMB 510 million, reflecting a year-on-year increase of approximately 108.9% to 126.7%. Adjusted EBITDA is projected to range from RMB 630 million to RMB 670 million, showing a year-on-year increase of 40.6% to 49.6%.

AI Applications Intensify: Products with “Tens of Millions” Monthly Recharge Set to Expand in Three Years

In the first half of 2025, the social networking business delivered robust profit growth. According to the announcement, the growth was driven by the continued expansion of diversified social products supported by AI technology, as well as the complete consolidation of NBT Social Networking Inc.’s financials following the acquisition of its non-controlling interests in December 2024.

Newborn Town’s global product portfolio continued to scale across markets. While flagship products like MICO and YoHo remained as steady contributors of profit and cash flow, the revenue contribution from newer products such as SUGO and TopTop continued to rise in the first half of 2025.

During this period, Newborn Town also made significant strides in key markets like MENA. Through refined operational strategies, Newborn Town has enhanced user experience and monetization efficiency, further unlocking the market’s vast potential. Meanwhile, the company has been deepening its “product replication + country replication” strategy to actively explore new markets. Currently, some products have already successfully entered these new regions.

AI continues to empower the Group’s products with deeper applications across operational scenarios. The self-developed multimodal algorithm Boomiix continues to be upgraded, enhancing social matching precision and intelligent operations, particularly effective in user acquisition across new markets and long-tail user engagement. Each key part of the R&D function of the company also applied AI technology to improve efficiency. For example, the self-development internal AIGC tools adopted by the design team have significantly enhanced efficiency in areas like virtual gift remix, animation effects addition and graphic design.   

With deeper market understanding, stronger localized operations, and broader AI integration, the Group is accelerating the pace of blockbuster product incubation. Over the next three years, two new products under development are expected to reach monthly recharge exceeding USD 10 million, further expanding the scale of the social networking business.

The Group’s diverse-audience social networking business sustained solid development in global markets. Through iterating social features and deepening content ecosystems, user experience and engagement depth under the business segment further improved. In addition, brand campaigns and social responsibility initiatives have elevated overall brand awareness and influence. At the beginning of 2025, HeeSay GALA events were held in Thailand and the Philippines, encouraging users to co-create vibrant, diverse community ecosystems with HeeSay.

Innovative Business Accelerated Growth, with Global Expansion Entering a New Phase

In the first half of 2025, as the moat around the social networking business continues to strengthen, Newborn Town’s second growth curve – powered by quality games and social e-commerce – has become increasingly mature. Revenue from the innovative business is expected to reach RMB 335 million to RMB 355 million, up approximately 65.0% to 74.9% year-on-year.

According to the announcement, the growth was driven by solid traffic monetization and social e-commerce performance, as well as contributions from quality games, which began monetizing in Q4 2024. 

Social e-commerce saw a notable performance boost, driven by upgraded user services, diversified business ecosystem, and expanded acquisition channels. In the first half of 2025, Heer Health achieved steady growth, further solidifying its leadership in the sexual health service and HIV prevention and control segments.

Following its initial revenue contribution last year, Newborn Town’s quality games segment officially entered a profit-generating phase in 2025. Flagship product, Alice’s Dream: Merge Games moved into long-term operation, delivering steady returns. Leveraging its experience in the merge-game category, the Group has significantly shortened development cycles. Key metrics such as user retention and ARPU have remained strong, while new game development is progressing smoothly.

In June 2025, Newborn Town officially established its global headquarters in Hong Kong, marking another milestone in the company’s worldwide expansion and signaling a new chapter in its globalization strategy.

Moving forward, the company will leverage Hong Kong as a strategic global hub, working closely with its R&D and operations centers worldwide. Through technological innovation and localized operations, Newborn Town will further expand its global business and create positive emotional value to users worldwide.